You are here:

clostridium botulinum toxin A (Dysport)

Advice

Following a re-submission:

clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) is accepted for restricted use within NHS Scotland.

Indication under review: for focal spasticity, including the treatment of arm symptoms associated with focal spasticity in conjunction with physiotherapy.

SMC restriction: for focal spasticity of the upper limbs associated with stroke.

Clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) produces a localised reduction in muscle tone in patients with post-stroke upper limb spasticity and can improve patient disability at 16 weeks. It continues to be effective after repeated administrations with no new adverse events apparent.

Drug Details

Drug Name: clostridium botulinum toxin A (Dysport)
SMC Drug ID: 353/07
Manufacturer: Ipsen Ltd
Indication: For the treatment of focal spasticity, including arm symptoms associated with focal spasticity, in conjunction with physiotherapy.
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 14 January 2013

Archived Advice

Full submission 12 March 2007

Extra Notes

The use of botulinum toxin type A in upper limb spasticity has become established according to local protocols. An extension to the licensed indication for an alternative botulinum toxin type A-containing  medicine to remove the limitation to patients post stoke will not be assessed by SMC. Consequently, no SMC advice will be issued for the use of botulinum toxin type A (Dysport) in the full licensed indication “focal spasticity of upper limbs in adults”. Use of botulinum toxin type A in upper limb spasticity should be in line with local formulary decisions.

Back